Hans S Brink

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
New therapeutic agents are warranted in idiopathic membranous nephropathy. Synthetic ACTH may be advantageous with reported remission rates up to 85% and few side effects. We conducted a prospective open label cohort study from 2008 till 2010 (NCT00694863). We prospectively selected patients with idiopathic membranous nephropathy and high risk for(More)
  • 1